Search

UCB SA

Atidarymo kaina

SektoriusSveikatos priežiūra

171.7 -0.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

171.15

Max

174.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

857M

Pardavimai

3.4B

P/E

Sektoriaus vid.

31.43

39.857

Dividendų pajamingumas

0.83

Pelno marža

25.498

Darbuotojai

9,052

EBITDA

1.3B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+19.23% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.83%

2.42%

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.9B

33B

Ankstesnė atidarymo kaina

172.65

Ankstesnė uždarymo kaina

171.7

Naujienos nuotaikos

By Acuity

50%

50%

169 / 376 reitingas Healthcare

UCB SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-17 23:34; UTC

Įsigijimai, susijungimai, perėmimai

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

2025-07-17 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

2025-07-17 21:04; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

2025-07-17 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Position Adjustments -- Market Talk

2025-07-17 23:42; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

2025-07-17 22:47; UTC

Įsigijimai, susijungimai, perėmimai

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

2025-07-17 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

2025-07-17 22:46; UTC

Įsigijimai, susijungimai, perėmimai

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

2025-07-17 22:43; UTC

Įsigijimai, susijungimai, perėmimai

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

2025-07-17 22:43; UTC

Įsigijimai, susijungimai, perėmimai

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

2025-07-17 22:40; UTC

Įsigijimai, susijungimai, perėmimai

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

2025-07-17 22:40; UTC

Įsigijimai, susijungimai, perėmimai

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

2025-07-17 22:30; UTC

Rinkos pokalbiai
Uždarbis

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

2025-07-17 22:20; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-07-17 22:20; UTC

Rinkos pokalbiai
Uždarbis

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

2025-07-17 22:04; UTC

Rinkos pokalbiai
Uždarbis

Netflix Redesign Done to Match Current Capabilities -- Market Talk

2025-07-17 22:03; UTC

Įsigijimai, susijungimai, perėmimai

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

2025-07-17 21:58; UTC

Rinkos pokalbiai
Uždarbis

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

2025-07-17 21:57; UTC

Uždarbis

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

2025-07-17 21:47; UTC

Uždarbis

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

2025-07-17 21:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-17 21:45; UTC

Rinkos pokalbiai

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

2025-07-17 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

2025-07-17 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

2025-07-17 21:05; UTC

Uždarbis

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

2025-07-17 21:04; UTC

Įsigijimai, susijungimai, perėmimai

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

2025-07-17 21:02; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

2025-07-17 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

2025-07-17 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

UCB SA Prognozė

Kainos tikslas

By TipRanks

19.23% į viršų

12 mėnesių prognozė

Vidutinis 94.86 EUR  19.23%

Aukščiausias 125 EUR

Žemiausias 74 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines UCB SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

4

Pirkti

1

Laikyti

2

Parduoti

Rinkos nuotaikos

By Acuity

169 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.